Placeholder Banner

BIO Comments on Proposed Changes to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules

October 16, 2018

BIO submitted comments to the National Institutes of Health (NIH) regarding the Proposed Changes to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.

BIO applauds the NIH’s efforts to support and advance drug development for gene therapies, by streamlining protocol registration and reporting requirements and by modifying the roles and responsibilities of the Recombinant DNA Advisory Committee. BIO agrees with the goal to eliminate duplication and excess in regulation of gene therapy products, as these redundancies do not exist in most other areas of clinical research. BIO believes there is sufficient and robust regulatory framework already in place for safe and effective development of gene therapy products.

BIO also proposes changes to the requirement for an Institutional Biosafety Committee (IBC) approval of a study site before initiation of a study.

Download Full Comments Below
FINAL BIO Comments On NIH OSP Nucleic Acid Research 10-12-18
Read the full comment letter below
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…